SeekingAlphaAugust 5, 2026 at 9:50 AM NYlast month
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
Stoke Therapeutics stays a Buy as zorevunersen hits key Dravet milestones and STK-002 advances; strong cash runway to 2028. Click for more on STOK stock.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Yahoo4 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill41 minutes ago
Sector Update: Financial
Yahoo2 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo2 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill2 hours ago